Microsatellite-stable (MSS) colorectal cancer (CRC) is a molecularly complex and clinically challenging disease subtype, lacking effective targeted therapies. Leveraging multiomic data from ∼2,000 tumor samples (including 316MSS CRCs not previously profiled) representing ∼4,500 molecular profiles and 195,246 single cel...
A. Sadanandam, A. O'Farrell, I. Miller et al.· Cancer Cell· 1 citation
Tumor heterogeneity is a major determinant of tumor progression and therapeutic resistance, yet the contribution of metabolism to intratumoral heterogeneity still remains poorly explored. Here, we find that pyruvate dehydrogenase kinase-1 (Pdk1) expression defines metabolically distinct cancer cell populations in color...
Jessica Calviello, Lisa Pöltl, Alessia Mira et al.· bioRxiv· 0 citations
Dual MEK and mTORC1/2 blockade resulted in synergistic antiproliferative effects in cell lines bearing alterations in KRAS/BRAF and PIK3CA/PTEN and a marked proapoptotic response to therapy was observed exclusively in wild-type TP53 colorectal cancer models.
Celina García-García, M. Rivas, Y. Ibrahim et al.· 0 citations
This review will focus on the MET pathway and its role in resistance to EGFR TK (tyrosine kinase) inhibitors, the different strategies of its inhibition, and the potential approaches to overcoming acquired resistance.
F. Gelsomino, F. Facchinetti, E. Haspinger et al.· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.